Answers are grounded in this paper and cite their sources.
Progress in the field of passive immunoprophylaxis for protection of high-risk infants and children against respiratory syncytial virus (RSV) infection has achieved remarkable success. Palivizumab was licensed by the United States Food and Drug Administration (FDA) in 1998 for monthly intramuscular administration for prevention of RSV lower respiratory tract infections in high-risk infants and children. The annual rate of hospitalization due to RSV infection among infants in high-risk groups who do not receive immunoprophylaxis varies between 10% and 20%, a figure that is ∼5 times higher than the hospitalization rate among non–high-risk infants. Results from 2 blinded, randomized, placebo-controlled trials involving 2789 infants and children with prematurity, chronic lung disease, or congenital heart disease demonstrated a reduction in RSV hospitalization rates of between 39% and 78% in different groups.1,2 Results from postlicensure, observational studies suggest that monthly immunoprophylaxis with palivizumab may reduce rates of RSV-induced hospitalization to an even greater extent than rates reported in the well-conducted IMpact-RSV trial, which led to licensure by the FDA.3 Data confirming the safety of palivizumab have been published in a report from the FDA.4 In view of the welcome advancement in disease prevention offered by palivizumab immunoprophylaxis against the most common cause of hospitalization in the first year of life, why does controversy surround the use of this intervention?Consideration of an intervention that has been proven effective needs to include its costs and benefits and recognize that dollars spent on this intervention may not be available for other equally important interventions. One of the most effective prevention strategies for infectious diseases has been active immunization using vaccines. Cost savings or cost-effectiveness can be demonstrated readily for many vaccines (Haemophilus influenzae type b, measles, and polio vaccines).5 For some recently introduced vaccines (conjugated pneumococcal vaccine, varicella vaccine), cost-effectiveness is more difficult to document, and some vaccines that may be added to the recommended childhood immunization schedule in the future may not be cost-effective when using standard approaches to estimate costs and benefits. For effective but costly disease interventions such as immunoprophylaxis with palivizumab, the impact of decisions on use can be substantial to both the patient and the health care system. The tension between the individual patient perspective and health care system perspective has fueled discussion about palivizumab prophylaxis. Strategies that limit the cost of palivizumab prophylaxis while maintaining protection of the patient will produce the most favorable cost-benefit ratio. Because one of the key drivers of the cost of prophylaxis is the number of monthly doses administered, strategies that focus administration of palivizumab during months when RSV infection is most likely to occur should protect the patient from RSV disease and the health care system from unnecessary costs.In the Northern Hemisphere and particularly within the United States, RSV circulates predominantly between November and March, followed by a peak in activity in the Southern Hemisphere.6 In equatorial countries, RSV tends to cause disease throughout the year, with increased activity associated with rainfall and a decrease in temperature.7 Within the United States, the inevitability of the RSV season is predictable, but the severity of the season, the time of onset, the peak of activity, and the end of the season cannot be predicted precisely. There can be substantial variation in timing of community outbreaks of RSV disease from year to year in the same community and between communities in the same year even in the same region. This variation, however, occurs within the overall pattern of RSV outbreaks, usually beginning in November or December, peaking in January or February, and ending by March. Communities in the southern region tend to experience the earliest onset of RSV activity, and midwestern states tend to experience the latest onset, but community-to-community variation in timing precludes using either national or regional data to precisely define or predict individual community RSV outbreaks. The duration of the season for western and northeast regions typically occurs between that noted in the South and the Midwest. In recent years, the national median duration of the RSV season has been 15 weeks, and even in the South with seasonal duration of 16 weeks, the range is 13 to 20 weeks.6 Data on likely RSV-associated hospitalizations suggest that RSV disease matches the conclusions from RSV-detection data; 81% of hospitalizations due to bronchiolitis in infants and young children occur from November through April.8 Bronchiolitis outbreaks are correlated closely with RSV detection, and many prospective studies have found that most hospitalizations for bronchiolitis are caused by RSV.The recommendation for 5 monthly doses of palivizumab was derived from the design of clinical trials with both RespiGam and palivizumab. In the IMpact-RSV trial and in the trial involving children with hemodynamically significant congenital heart disease, 5 monthly doses of palivizumab resulted in serum concentrations ≥30 μg/mL for >20 weeks in almost all subjects.1,2 A serum palivizumab concentration ≥30 μg/mL is the proposed serologic correlate of protection, derived from the cotton rat model, in which this concentration results in a decrease in pulmonary RSV replication by >100-fold.9 One month after the fourth monthly dose of palivizumab, the mean serum trough concentration was 72 μg/mL among subjects in the IMpact-RSV trial and 90 μg/mL in subjects in the cardiac trial, indicating that the trough serum level >30 days after the fifth dose will be >30 μg/mL for most children.1,2 Thus for most infants, 5 monthly doses of palivizumab will provide substantially >20 weeks of serum antibody levels, which should be protective and cover most of the RSV season even with variation in season onset and end.The cost and benefit of RSV prophylaxis is determined by yearly risks of disease. The cost and benefit of adding a month of prophylaxis should be based, in turn, on the added cost of palivizumab and the risk of severe disease for that month (risk of infection times risk of RSV hospitalization for the patient). Thus, the greatest cost savings will occur during the peak outbreak months, and the least cost savings will occur during the early and late months of the RSV season. The lower cost savings for the early and late outbreak periods is compounded by the specificity of the RSV diagnostic assay. Antigen-detection tests have proven useful in diagnosing RSV infection, but as with all tests, the positive predictive value (the likelihood that a positive test is truly positive, not a false-positive result) decreases as disease incidence goes down. Sensitivity and specificity of antigen-detection assays are low at both the onset and the end of the season,6,10 which suggests that the risk to the child in these periods will be less than that predicted by RSV detection using antigen-based assays.The American Academy of Pediatrics policy issued in December 2003 considered both the opportunity to reduce the incidence of RSV hospitalizations in infants and children at greatest risk and the cost of prophylaxis when recommending that “in most seasons and in most regions of the Northern Hemisphere, the first dose of palivizumab should be administered at the beginning of November, and the last dose should be administered at the beginning of March, which will provide protection into April.”11 Changes from this recommendation require careful consideration of the benefits and costs as well as data on timing of RSV outbreaks and associated disease using appropriate diagnostic criteria.
No takes yet. Share an insight, caveat, or question.
Meissner et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: